AstraZeneca

AZNPhase 3

AstraZeneca is one of the world's largest pharmaceutical companies, headquartered in Cambridge, UK, with a market capitalization of approximately $285 billion. The company focuses on transformative science including next-generation therapeutics, AI-driven drug discovery, and personalized medicine approaches. AstraZeneca reported strong commercial performance in 2025 with 16 positive Phase 3 study results announced during the year, demonstrating continued pipeline strength across multiple therapeutic areas.

Market Cap

$17.7B

Employees

80,000+

Focus

AntibodiesBiologicsSmall Molecules

AZN · Stock Price

USD 29.92+19.83 (+196.69%)

Historical price data

AI Company Overview

Technology Platform

AstraZeneca leverages AI-driven drug discovery, genomics, multi-omics integration, and next-generation therapeutic modalities including oligonucleotides, mRNA, and bicyclic peptides to advance precision medicine and accelerate drug development.

Pipeline Snapshot

1000

1000 drugs in pipeline, 826 in Phase 3

Drug	Indication	Stage
Tozorakimab + Placebo	Viral Lung Infection and Acute Respiratory Failure	Phase 3
Saruparib (AZD5305) + Camizestrant + Abemaciclib + Ribociclib + Palbociclib + Fulvestrant + Letrozole + Anastrozole + Exemestane	Advanced Breast Cancer	Phase 3
Dapagliflozin + Metformin + Sitagliptin + Placebo	Type 2 Diabetes Mellitus	Phase 3
Olaparib + Paclitaxel + Placebo	Gastric Cancer	Phase 3
Ciclesonide + Placebo	Asthma	Phase 3

Funding History

IPOUndisclosedUndisclosedApr 6, 1993

FDA Approved Drugs

KOSELUGONDASep 10, 2025

WAINUA (AUTOINJECTOR)NDADec 21, 2023

TRUQAPNDANov 16, 2023

Opportunities

AstraZeneca has significant growth opportunities through its robust pipeline of 197 projects, advanced AI and genomics capabilities, and expansion in emerging markets.

The company's focus on next-generation therapeutics and personalized medicine positions it well for the evolving healthcare landscape.

Risk Factors

Key risks include regulatory challenges for drug approvals, potential patent cliffs for blockbuster products, and intense competitive pressure in core therapeutic areas.

Clinical trial failures and global pricing pressures also pose ongoing challenges.

Competitive Landscape

AstraZeneca competes with pharmaceutical giants like Pfizer, Roche, and Novartis but differentiates through its strong oncology portfolio, leadership in respiratory diseases, and advanced AI-driven drug discovery capabilities. Strategic partnerships and novel therapeutic modalities provide additional competitive advantages.

Publications

Patents

Pipeline

1000

FDA Approvals